Depression bei Morbus Parkinson: Epidemiologie und Therapie

O. Riedel; R. Dodel; K. Rohde; H.-U. Wittchen

doi:10.1055/s-0033-1359892

Aktuelle Neurologie, Table of Contents

Aktuelle Neurologie 2013; 40(10): 574-587
DOI: 10.1055/s-0033-1359892

Fort- und Weiterbildung

Depression bei Morbus Parkinson: Epidemiologie und Therapie

Depression in Parkinson’s Disease: Epidemiology and Treatment

Authors

O. Riedel

¹Technische Universität Dresden, Institut für Klinische Psychologie und Psychotherapie
R. Dodel

²Philipps-Universität Marburg, Klinik für Neurologie
K. Rohde

³Division für Neurodegenerative Erkrankungen, Klinik und Poliklinik für Neurologie, Technische Universität Dresden
H.-U. Wittchen

¹Technische Universität Dresden, Institut für Klinische Psychologie und Psychotherapie

Abstract

Full Text

References

Literatur
1 Parkinson J. An Essay on the Shaking Palsy. London: Sherwood, Neely and Jones; 1817
2 Schrag A, Jahanshahi M, Quinn N. How does Parkinson’s disease affect quality of life? A comparison with quality of life in the general population. Movement Disord 2000; 15: 1112-1118
3 Bach J-P, Riedel O, Klotsche J et al. Impact of complications and comorbidities on treatment costs and health-related quality of life in patients with Parkinson’s disease. J Neurol Sci 2012; 314: 41-47
4 Winter Y, Balzer-Geldsetzer M, Spottke A et al. Longitudinal study of the socioeconomic burden of Parkinson’s disease in Germany. Eur J Neurol 2010; 17: 1156-1163
5 Gallagher DA, Schrag A. Psychosis, apathy, depression and anxiety in Parkinson’s disease. Neurobiol Dis 2012; 46: 581-589
6 Reijnders J, Ehrt U, Weber WEJ et al. A systematic review of prevalence studies of depression in Parkinson’s disease. Movement Disord 2008; 23: 183-189
7 Leentjens AFG. Depression in Parkinson’s disease: conceptual issues and clinical challenges. J Geriatr Psychiat Neurol 2004; 17: 120-126
8 Farabaugh AH, Locascio JJ, Yap L et al. Assessing depression and factors possibly associated with depression during the course of Parkinson’s disease. Ann Clin Psychiatry 2011; 23: 171-177
9 Hu M, Cooper J, Beamish R et al. How well do we recognise non-motor symptoms in a British Parkinson’s disease population?. J Neurol 2011; 258: 1513-1517
10 Marsh L, McDonald WM, Cummings J et al. Provisional diagnostic criteria for depression in Parkinson’s disease: Report of an NINDS/NIMH work group. Movement Disord 2006; 21: 148-158
11 Zheng J, Sun SG, Qiao X et al. Depression in patients with Parkinson’s disease and the associated features. J Huazhong Univ Sci Tech-Med 2009; 29: 725-728
12 Joutsa J, Martikainen K, Vahlberg T et al. Impulse control disorders and depression in Finnish patients with Parkinson’s disease. Parkinsonism Relat Disord 2012; 18: 155-160
13 Piccinni A, Marazziti D, Veltri A et al. Depressive symptoms in Parkinson’s disease. Compr Psychiat 2012; 53: 727-731
14 Bugalho P, da Silva JA, Cargaleiro I et al. Psychiatric symptoms screening in the early stages of Parkinson’s disease. J Neurol 2012; 259: 124-131
15 Coelho M, Marti MJ, Tolosa E et al. Late-stage Parkinson’s disease: the Barcelona and Lisbon cohort. J Neurol 2010; 257: 1524-1532
16 Riedel O, Heuser I, Klotsche J et al. Occurrence risk and structure of depression in Parkinson disease with and without dementia: results from the GEPAD study. J Geriatr Psychiat Neurol 2010; 23: 27-34
17 Cummings JL, Masterman DL. Depression in patients with Parkinson’s disease. Int J Geriatr Psychiatr 1999; 14: 711-718
18 Spica V, Pekmezovic T, Svetel M et al. Prevalence of non-motor symptoms in young-onset versus late-onset Parkinson’s disease. J Neurol 2013; 260: 131-137
19 Anguenot A, Loll PY, Neau JP et al. Depression and Parkinson’s disease: a study of 135 parkinsonian patients. Can J Neurol Sci 2002; 29: 139-146
20 Burn DJ, Landau S, Hindle JV et al. Parkinson’s disease motor subtypes and mood. Movement Disord 2012; 27: 379-386
21 Schrag A, Jahanshahi M, Quinn NP. What contributes to depression in Parkinson’s disease?. Psychol Med 2001; 31: 65-73
22 Starkstein SE, Petracca G, Chemerinski E et al. Depression in classic versus akinetic-rigid Parkinson’s disease. Movement Disord 1998; 13: 29-33
23 Holroyd S, Currie LJ, Wooten GF. Depression is associated with impairment of ADL, not motor function in Parkinson disease. Neurology 2005; 64: 2134-2135
24 Kessler RC, Petukhova M, Sampson NA et al. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res 2012; 21: 169-184
25 Solla P, Cannas A, Ibba FC et al. Gender differences in motor and non-motor symptoms among Sardinian patients with Parkinson’s disease. J Neurol Sci 2012; 323: 33-39
26 Jacob EL, Gatto NM, Thompson A et al. Occurrence of depression and anxiety prior to Parkinson’s disease. Parkinsonism Relat Disord 2010; 16: 576-581
27 Poletti M, De Rosa A, Bonuccelli U. Affective symptoms and cognitive functions in Parkinson’s disease. J Neurol Sci 2012; 317: 97-102
28 Riedel O, Klotsche J, Spottke A et al. Cognitive impairment in 873 patients with idiopathic Parkinson’s disease: results from the German Study on Epidemiology of Parkinson’s Disease with Dementia (GEPAD). J Neurol 2008; 255: 255-264
29 Starkstein S, Dragovic M, Jorge R et al. Diagnostic criteria for depression in Parkinson’s disease: a study of symptom patterns using latent class analysis. Movement Disord 2011; 26: 2239-2245
30 Morgante L, Colosimo C, Antonini A et al. Psychosis associated to Parkinson’s disease in the early stages: relevance of cognitive decline and depression. J Neurol Neurosurg Psychiatry 2012; 83: 76-82
31 Ziropadja L, Stefanova E, Petrovic M et al. Apathy and depression in Parkinson’s disease: the Belgrade PD study report. Parkinsonism Relat Disord 2012; 18: 339-342
32 Aarsland D, Pahlhagen S, Ballard CG et al. Depression in Parkinson disease – epidemiology, mechanisms and management. Nat Rev Neurol 2012; 8: 35-47
33 Dooneief G, Mirabello E, Bell K et al. An estimate of the incidence of depression in idiopathic Parkinson’s disease. Arch Neurol 1992; 49: 305-307
34 Dissanayaka NNW, Sellbach A, Silburn PA et al. Factors associated with depression in Parkinson’s disease. J Affect Disord 2011; 132: 82-88
35 Kulkantrakorn K, Jirapramukpitak T. A prospective study in one year cumulative incidence of depression after ischemic stroke and Parkinson’s disease: a preliminary study. J Neurol Sci 2007; 263: 165-168
36 Leentjens A, van den Akker M, Metsemakers J et al. Higher incidence of depression preceding the onset of Parkinson’s disease: a register study. Movement Disord 2003; 18: 414-418
37 Nilsson FM, Kessing LV, Bolwig TG. Increased risk of developing Parkinson’s disease for patients with major affective disorder: a register study. Acta Psychiatr Scand 2001; 104: 380-386
38 Skeie GO, Muller B, Haugarvoll K et al. Parkinson disease: associated disorders in the Norwegian population based incident ParkWest study. Parkinsonism Relat Disord 2013; 19: 53-55
39 Meara J, Mitchelmore E, Hobson P. Use of the GDS-15 geriatric depression scale as a screening instrument for depressive symptomatology in patients with Parkinson’s disease and their carers in the community. Age and Ageing 1999; 28: 35-38
40 Osborn DPJ, Fletcher A, Smeeth L et al. Geriatric depression scale scores in a representative sample of 14545 people aged 75 and over in the United Kingdom: results from the MRC Trial of Assessment and Management of Older People in the Community. Int J Geriatr Psychiatr 2002; 17: 375-382
41 Leentjens A, Verhey F, Lousberg R et al. The validity of the Hamilton and Montgomery-Asberg depression rating scales as screening and diagnostic tools for depression in Parkinson’s disease. Int J Geriatr Psychiatr 2000; 15: 644-649
42 Schrag A, Barone P, Brown R et al. Depression rating scales in Parkinson’s disease: critique and recommendations. Movement Disord 2007; 22: 1077-1092
43 DGPPN, BÄK, KBV et al. eds. S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression – Kurzfassung. Berlin, Düsseldorf: 2009
44 Seppi K, Weintraub D, Coelho M et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson’s disease. Movement Disord 2011; 26: S42-S80
45 Chaudhuri KR, Martinez-Martin P, Antonini A et al. Rotogotine and specific non-motor symptoms of Parkinson’s disease: post-hoc analysis of RECOVER. Parkinsonism Relat Disord 2013; 19: 660-665
46 Franco-Chaves J, Mateus C, Luckenbaugh D et al. Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: a double-blind, randomized pilot study. J Affect Disord 2013; 149: 319-325
47 Korchounov A, Winter Y, Rossy W. Combined beneficial effect of rasagiline on motor function and depression in de novo PD. Clin Neuropharmacol 2012; 35: 121-124
48 Richard IH, McDermott MP, Kurlan R et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012; 78: 1229-1236
49 Bertaina-Anglade V, La Rochelle CD, Scheller DKA. Antidepressant properties of rotigotine in experimental models of depression. Eur J Pharmacol 2006; 548: 106-114
50 Bauer M, Whybrow PC, Angst J et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of unipolar depressive disorders, part 2: maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. Rev Psiquiatr Clin 2009; 36: 58-76
51 Devos D, Dujardin K, Poirot I et al. Comparison of desipramine and citalopram treatments for depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Movement Disord 2008; 23: 850-857
52 Wermuth L, Sorensen PS, Timm S et al. Depression in idiopathic Parkinson’s disease treated with citalopram. A placebo-controlled trial. Nord J Psychiatr 1998; 52: 163-169
53 Avila A, Cardona X, Martin-Baranera M et al. Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial. J Clin Psychopharmacol 2003; 23: 509-513
54 Fregni F, Santos CM, Myczkowski ML et al. Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 2004; 75: 1171-1174
55 Leentjens AFG, Vreeling FW, Luijckx GJ et al. SSRIs in the treatment of depression in Parkinson’s disease. Int J Geriatr Psychiatr 2003; 18: 552-554
56 Antonini A, Tesei S, Zecchinelli A et al. Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson’s disease and depression: effect on quality of life. Movement Disord 2006; 21: 1119-1122
57 Barone P, Scarzella L, Marconi R et al. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease – a national multicenter parallel-group randomized study. J Neurol 2006; 253: 601-607
58 Weintraub D, Mavandadi S, Mamikonyan E et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 2010; 75: 448-455
59 Therapies for depression in Parkinson’s disease. Cochrane Database Syst Rev 2003;
60 Takahashi H, Kamata M, Yoshida K et al. Remarkable effect of milnacipran, a serotonin-noradrenalin reuptake inhibitor (SNRI), on depressive symptoms in patients with Parkinson’s disease who have insufficient response to selective serotonin reuptake inhibitors (SSRIs): two case reports. Prog Neuro-Psychopharmacol Biol Psychiatry 2005; 29: 351-353
61 Lemke MR. Effect of reboxetine on depression in Parkinson’s disease patients. J Clin Psychiatry 2002; 63: 300-304
62 Leentjens AFG, Verhey FRJ, Vreeling FW. Successful treatment of depression in Parkinson’s disease patient with bupropion. Ned Tijdschr Geeeskd 2000; 144: 2157-2159
63 Stoppe G. Depressionen im Alter. Bundesgesundheitsblatt 2008; 51: 406-410
64 Ehrt U, Bronnick K, Leentjens AFG et al. Depressive symptom profile in Parkinson’s disease: a comparison with depression in elderly patients without Parkinson’s disease. Int J Geriatr Psychiatr 2006; 21: 252-258
65 Gotham AM, Brown RG, Marsden CD. Depression in Parkinson’s disease – a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 1986; 49: 381-389
66 Merschdorf U, Berg D, Csoti I et al. Psychopathological symptoms of depression in Parkinson’s disease compared to major depression. Psychopathol 2003; 36: 221-225
67 Kummer A, Cardoso F, Teixeira AL. Suicidal ideation in Parkinson’s disease. CNS Spectr 2009; 14: 431-436
68 Funkiewiez A, Ardouin C, Caputo E et al. Long-term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2004; 75: 834-839
69 Soulas T, Gurruchaga JM, Palfi S et al. Attempted and completed suicides after subthalamic nucleus stimulation for Parkinson’s disease. J Neurol Neurosurg Psychiatry 2008; 79: 952-954
70 Strutt AM, Simpson R, Jankovic J et al. Changes in cognitive-emotional and physiological symptoms of depression following STN-DBS for the treatment of Parkinson’s disease. Eur J Neurol 2012; 19: 121-127
71 Voon V, Krack P, Lang AE et al. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson’s disease. Brain 2008; 131: 2720-2728
72 Toft M, Lilleeng B, Ramm-Pettersen J et al. Long-Term efficacy and mortality in Parkinson’s disease patients treated with subthalamic stimulation. Movement Disord 2011; 26: 1931-1934
73 Cole K, Vaughan FL. The feasibility of using cognitive behaviour therapy for depression associated with Parkinson’s disease: a literature review. Parkinsonism Relat Disord 2005; 11: 269-276
74 Dobkin RD, Menza M, Allen LA et al. Cognitive-behavioral therapy for depression in Parkinson’s disease: a randomized, controlled trial. Am J Psychiat 2011; 168: 1066-1074
75 Dobkin RD, Allen LA, Menza M. Cognitive-behavioral therapy for depression in Parkinson’s disease: a pilot study. Movement Disord 2007; 22: 946-952
76 Farabaugh A, Locascio JJ, Yap L et al. Cognitive-behavioral therapy for patients with Parkinson’s disease and comorbid major depressive disorder. Psychosomatics 2010; 51: 124-129
77 Dobkin RD, Menza M, Allen LA et al. Telephone-based cognitive-behavioral therapy for depression in Parkinson disease. J Geriatri Psychiatr Neurol 2011; 24: 206-214
78 Brand S, Dodel R, Hautzinger M et al. Depression in Parkinson’s disease. Assessment and treatment. Nervenarzt 2007; 78: 715-727
79 Dobkin RD, Rubino JT, Allen LA et al. Predictors of treatment response to cognitive-behavioral therapy for depression in Parkinson’s disease. J Consult Clin Psychol 2012; 80: 694-699
80 Sproesser E, Viana MA, Quagliato E et al. The effect of psychotherapy in patients with PD: a controlled study. Parkinsonism Relat Disord 2010; 16: 298-300
81 A’Campo LEI, Wekking EM, Spliethoff-Kamminga NGA et al. The benefits of a standardized patient education program for patients with Parkinson’s disease and their caregivers. Parkinsonism Relat Disord 2010; 16: 89-95
82 A’Campo LEI, Wekking EM, Spliethoff-Kamminga NGA et al. Treatment effect modifiers for the patient education programme for Parkinson’s disease. Int J Clin Pract 2012; 66: 77-83
83 Macht M, Gerlich C, Ellgring H et al. Patient education in Parkinson’s disease: formative evaluation of a standardized programme in seven European countries. Patient Educ Couns 2007; 65: 245-252
84 Fitzpatrick L, Simpson J, Smith A. A qualitative analysis of mindfulness-based cognitive therapy (MBCT) in Parkinson’s disease. Psychol Psychother-Theory Res Pract 2010; 83: 179-192
85 Strehl U, Birbaumer N. Verhaltensmedizinische Interventionen beim Morbus Parkinson. Weinheim: Beltz; 1996
86 Yang S, Sajatovic M, Walter BL. Psychosocial interventions for depression and anxiety in Parkinson’s disease. J Geriatr Psychiatr Neurol 2012; 25: 113-121
87 Hemmeter U, Hemmeter-Spernal J, Krieg J. Sleep deprivation in depression. Expert Rev Neurother 2010; 10: 1101-1115
88 Demet EM, Chicz-Demet A, Fallon JH et al. Sleep deprivation therapy in depressive illness and Parkinson’s disease. Prog Neuro-Psychopharmacol Biol Psychiatry 1999; 23: 753-784
89 Willis GL, Moore C, Armstrong SM. A historical justification for and retrospective analysis of the systematic application of light therapy in Parkinson’s disease. Rev Neurosci 2012; 23: 199-226
90 Paus S, Schmitz-Hubsch T, Wullner U et al. Bright light therapy in Parkinson’s disease: a pilot study. Mov Disord 2007; 22: 1495-1498
91 Fregni F, Simon DK, Wu A et al. Non-invasive brain stimulation for Parkinson’s disease: a systematic review and meta-analysis of the literature. J Neurol Neurosurg Psychiatr 2005; 76: 1614-1623
92 Pal E, Nagy F, Aschermann Z et al. The impact of left prefrontal repetitive transcranial magnetic stimulation on depression in Parkinson’s disease: a randomized, double-blind, placebo-controlled study. Movement Disord 2010; 25: 2311-2317
93 Arun MP, Bharath S, Pal PK et al. Relationship of depression, disability, and quality of life in Parkinson’s disease: a hospital-based case-control study. Neurol India 2011; 59: 185-189
94 Barone P, Antonini A, Colosimo C et al. The Priamo Study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Movement Disord 2009; 24: 1641-1649
95 Braam AW, Beekman ATF, Dewey ME et al. Depression and parkinsonism in older Europeans: results from the EURODEP concerted action. Int J Geriatr Psychiatr 2010; 25: 679-687
96 Khedr EM, El Fetoh NA, Khalifa H et al. Prevalence of depression, anxiety, dementia and other non motor features of a large cohort of Egyptian Parkinson’s disease patients. Life Sci J 2012; 9: 509-518
97 Oguru M, Tachibana H, Toda K et al. Apathy and depression in Parkinson disease. J Geriatr Psychiatr Neurol 2010; 23: 35-41
98 Rodriguez-Violante M, Cervantes-Arriaga A, Berlanga-Flores C et al. Prevalence and determinants of depression in Mexican patients with Parkinson’s disease. Clin Neurol Neurosurg 2012; 114: 1293-1296
99 Vanderheyden JE, Gonce M, Bourgeois P et al. Epidemiology of major depression in Belgian parkinsonian patients. Acta Neurol Belg 2010; 110: 148-156